• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Eisai Ltd ADR (OP: ESALY )

    N/A UNCHANGED
    Last Price Updated: 3:59 PM EST, Jan 30, 2023 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Eisai Ltd ADR

    < Previous 1 2 3 4 5 6 7 Next >
    The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs
    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 17) 10x Genomics, Inc. (NASDAQ... 
    Via Benzinga
    Exposures Product Safety
    Bristol Myers Inks Licensing Pact For Eisai's Folate Receptor ADC Drug, Lays Out Over $3B For Rights
    Eisai Co Ltd (OTC: ESALY) and Bristol-Myers Squibb Co (NYSE: BMY) have entered into an exclusive global strategic collaboration agreement for the co-... 
    Via Benzinga
    Two Rate Hikes In 2023
    This afternoon our Fed chief Jerome Powell predicted there will be interest rate hikes faster than before. The news hit US stocks, gold, and bitcoin hard. 
    Via Talk Markets
    Topics Economy
    Exposures Interest Rates
    Continued Uncertainty
    Fear of another Fukushima yesterday late in the market day led to a rush out of energy-related shares, which included many without any nuclear risk at all. 
    Via Talk Markets
    Dreary Day
    Another dreary day and a renewed boost for cryptocurrency - and away from the classic inflation hedge, gold. 
    Via Talk Markets
    Happy Friday
    The inflation risk is being ignored by the US market now that there will probably not be a tax increase and may be higher prices for longer. 
    Via Talk Markets
    Unheeding Markets
    Today oil prices rose over $70. 
    Via Talk Markets
    Wednesday News And Catch-Up
    Today the US market resumed its attempt to hit a new record for the S&P 500 and Nasdaq, but not the DJIA. 
    Via Talk Markets
    Topics Stocks
    Exposures US Equities
    FDA surprise
    The big news out of China is that its import purchases of copper and iron sagged last month because its export markets are far less strong than earlier this year. 
    Via Talk Markets
    Exposures Product Safety
    Biogen's Alzheimer's Disease Treatment Earns FDA Approval
    Aducanumab becomes the first available treatment intended to stop patients with Alzheimer's disease from losing more memories. 
    Via The Motley Fool
    Exposures Product Safety
    Why Biogen Stock Is On Fire Today
    The biotech's controversial Alzheimer's disease drug got a green light from the FDA. 
    Via The Motley Fool
    Exposures Product Safety
    Merck/Eisai's Keytruda-Lenvima Combo Results in Better Health-Related Quality of Life Measures Compared to Sunitinib
    Merck & Co Inc (NYSE: MRK) has announced new data from Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial, which evaluated the combinations of Keytruda (pembrolizumab... 
    Via Benzinga
    A Better Switch
    Today the US market decided to rise because President Biden is pondering not linking his infrastructure project to a corporate tax increase. 
    Via Talk Markets
    Ahead Of Judgement Day, FDA Faces Test with Biogen's Alzheimer's Drug Decision
    U.S. regulators are slated to decide by Monday whether to approve Biogen Inc’s (NASDAQ: BIIB) much-talked-about Alzheimer’s disease drug, aducanumab.... 
    Via Benzinga
    Exposures Product Safety
    Fan Hit
    The 10-yr US treasury yield rose to 1.6% again. Later in the day, a rally was attempted, mostly for the meme shares. 
    Via Talk Markets
    Wonder Products
    Meme is alive and well. 
    Via Talk Markets
    Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates
    The FDA review machinery worked overtime in May, completing reviews of several drug applications. Except for stray rejections or delays, the agency churned out mostly positive... 
    Via Benzinga
    Exposures Product Safety
    More Inflationary Pressures
    Today, we saw more evidence of worrying inflationary pressures from the personal consumption index hitting 3.1% in April over prior April, up sharply from the March rise of 1.9%. 
    Via Talk Markets
    New New Deal Worries
    Nio is up 1.4% today on another round of Meme buying. 
    Via Talk Markets
    Good Times For Gold
    Gold is rising some more, in part as an alternative to crypto. 
    Via Talk Markets
    Sterling At Five-Year High
    Today markets are mixed because of currency factors, with sterling bullishness against the dollar and the euro. 
    Via Talk Markets
    Better Mood Day
    The US Treasury plans to require IRS reporting on US cryptocurrency trades of $10,000 and up to prevent tax evasion. 
    Via Talk Markets
    Why Biogen's June 7 Aducanumab PDUFA Date Is A High-Risk, High-Reward Catalyst
    As the day of reckoning for Biogen Inc.'s (NASDAQ: BIIB) controversial Alzheimer's product candidate aducanumab draws close, an analyst at Oppenheimer looked at the... 
    Via Benzinga
    A Down Day
    The tech wreck continues because inflation will hurt the costly stock sector more than others. 
    Via Talk Markets
    The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs
    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6) GT Biopharma, Inc. (NASDAQ:... 
    Via Benzinga
    Inflation Shock
    Markets are up because jobs data were much better than expected, below 500,000 for the first week since Covid-19 started last week. 
    Via Talk Markets
    Exposures COVID-19
    Tuesday Market Report
    Swiss ABB gained 0.8% more today after it reported on its Q1 today, confirming the pre-announced data from earlier in April. 
    Via Talk Markets
    Robots
    Teva is suffering from fear of the legal risks of its opioid misselling which is overriding good news of its newer drugs. 
    Via Talk Markets
    Electric Cancer Cure
    Most US stocks were down on fear of inflation and financial risks but then rose after lunch. 
    Via Talk Markets
    The Daily Biotech Pulse: Quidel Slides On Negative Pre-Announcement, Roche Gets Positive EMA Committee Recommendation, 3 IPOs
    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 22) AtriCure, Inc. (NASDAQ:... 
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.